Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one

9Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity. This study identifies statins plus dypridamole as a preclinically effective combination of approved agents.

Cite

CITATION STYLE

APA

Pandyra, A., & Penn, L. Z. (2014). Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one. Molecular and Cellular Oncology, 1(4). https://doi.org/10.4161/23723548.2014.969133

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free